Matches in SemOpenAlex for { <https://semopenalex.org/work/W2945165639> ?p ?o ?g. }
- W2945165639 endingPage "311" @default.
- W2945165639 startingPage "304" @default.
- W2945165639 abstract "L’objectif de cette étude était d’évaluer l’efficacité et la tolérance d’un complément de dose de protons pour les patients atteints d’un cancer du nasopharynx localement évolué. De novembre 1999 à septembre 2016, 17 patients atteints d’un cancer du nasopharynx de stade III–IVa ont été pris en charge au centre de protonthérapie d’Orsay de l’institut Curie. Les aires ganglionnaires cervicales bilatérales ont été traitées par des photons à la dose de 40–54 Gy. La tumeur et ses extensions microscopiques ont reçu une dose complémentaire de protons pour atteindre la dose de 70–78 Gy. Tous les patients ont reçu une chimiothérapie concomitante. Le contrôle local, la survie sans récidive et la survie globale ont été déterminés, ainsi que la toxicité aiguë et tardive. Les caractéristiques des patients étaient : un âge médian de 49 ans, le sexe masculin pour 71 % des cas, 88 % des cancers étaient de stade IVa avec une majorité T4N0M0 (82 %). La médiane de suivi était de 99 mois. Les probabilités de contrôle local et de survie globale actuarielle ont été respectivement 94 % et 88 % à 2 ans, 86 % et 74 % à 5 ans, 86 % et 66 % à 10 ans. La toxicité tardive de grade ≥ 3 a été la perte auditive (23,5 %) et une ostéo-radio-nécrose de l’os sphénoïde (5,9 %). Le complément de dose de protons semble donc une bonne alternative pour le traitement des cancers du nasopharynx localement évolués, en particulier pour ceux de stade T4N0M0. The aim of this study was to assess the treatment outcome and toxicity for patients with locally advanced nasopharyngeal carcinoma treated with a complementary dose with proton. Between November 1999 and September 2016, 17 patients have been treated for a stage III–IVa nasopharyngeal carcinoma in the proton therapy centre of Curie Institute. Bilateral lymph node in the neck (I–V levels) received from 40 to 54 Gy with photon beam. The primary tumor volume including microscopically extensions received a complementary dose with proton in order to reach the dose of 70 to 78 Gy. All the patients received a concomitant chemotherapy. The end-points of the study were loco-regional control, survival, and treatment-related toxicity. Patients characteristics were: median age 49, 71 % male, 88% stage IVa, with a majority (82%) of T4N0M0. The median follow-up was 99 months. The 2-, 5- and 10-year actuarial locoregional free survival and overall survival were 94% and 88%, 86% and 74%, and 86% and 66%, respectively. The grade ≥ 3 late adverse events were sphenoid bone radionecrosis (5.9%) and hearing loss (23.5%). This study showed that a complementary dose with proton seems to be a good option for the treatment of locally advanced nasopharyngeal carcinoma, particularly for T4N0M0." @default.
- W2945165639 created "2019-05-29" @default.
- W2945165639 creator A5007673034 @default.
- W2945165639 creator A5007724679 @default.
- W2945165639 creator A5010386214 @default.
- W2945165639 creator A5024814188 @default.
- W2945165639 creator A5029359997 @default.
- W2945165639 creator A5033344528 @default.
- W2945165639 creator A5034625542 @default.
- W2945165639 creator A5036675596 @default.
- W2945165639 creator A5044317616 @default.
- W2945165639 creator A5046764240 @default.
- W2945165639 creator A5056623718 @default.
- W2945165639 creator A5074701778 @default.
- W2945165639 creator A5079715350 @default.
- W2945165639 date "2019-07-01" @default.
- W2945165639 modified "2023-10-17" @default.
- W2945165639 title "Complément de dose de protons pour les cancers du nasopharynx localement évolués : une expérience de l’institut Curie" @default.
- W2945165639 cites W1687101703 @default.
- W2945165639 cites W1757407923 @default.
- W2945165639 cites W2018120900 @default.
- W2945165639 cites W2045352770 @default.
- W2945165639 cites W2053481573 @default.
- W2945165639 cites W2102310008 @default.
- W2945165639 cites W2105670857 @default.
- W2945165639 cites W2111714525 @default.
- W2945165639 cites W2114662815 @default.
- W2945165639 cites W2125919881 @default.
- W2945165639 cites W2129121210 @default.
- W2945165639 cites W2140110477 @default.
- W2945165639 cites W2149294014 @default.
- W2945165639 cites W2165468773 @default.
- W2945165639 cites W2167359560 @default.
- W2945165639 cites W2178947594 @default.
- W2945165639 cites W2214854399 @default.
- W2945165639 cites W2392247408 @default.
- W2945165639 cites W2526747727 @default.
- W2945165639 cites W2579941249 @default.
- W2945165639 cites W2592965701 @default.
- W2945165639 cites W2596589910 @default.
- W2945165639 cites W2604577110 @default.
- W2945165639 cites W2740894115 @default.
- W2945165639 cites W2775830207 @default.
- W2945165639 cites W2886133226 @default.
- W2945165639 cites W2516692534 @default.
- W2945165639 doi "https://doi.org/10.1016/j.canrad.2019.01.003" @default.
- W2945165639 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31138519" @default.
- W2945165639 hasPublicationYear "2019" @default.
- W2945165639 type Work @default.
- W2945165639 sameAs 2945165639 @default.
- W2945165639 citedByCount "3" @default.
- W2945165639 countsByYear W29451656392020 @default.
- W2945165639 countsByYear W29451656392021 @default.
- W2945165639 countsByYear W29451656392023 @default.
- W2945165639 crossrefType "journal-article" @default.
- W2945165639 hasAuthorship W2945165639A5007673034 @default.
- W2945165639 hasAuthorship W2945165639A5007724679 @default.
- W2945165639 hasAuthorship W2945165639A5010386214 @default.
- W2945165639 hasAuthorship W2945165639A5024814188 @default.
- W2945165639 hasAuthorship W2945165639A5029359997 @default.
- W2945165639 hasAuthorship W2945165639A5033344528 @default.
- W2945165639 hasAuthorship W2945165639A5034625542 @default.
- W2945165639 hasAuthorship W2945165639A5036675596 @default.
- W2945165639 hasAuthorship W2945165639A5044317616 @default.
- W2945165639 hasAuthorship W2945165639A5046764240 @default.
- W2945165639 hasAuthorship W2945165639A5056623718 @default.
- W2945165639 hasAuthorship W2945165639A5074701778 @default.
- W2945165639 hasAuthorship W2945165639A5079715350 @default.
- W2945165639 hasBestOaLocation W29451656391 @default.
- W2945165639 hasConcept C121332964 @default.
- W2945165639 hasConcept C29456083 @default.
- W2945165639 hasConcept C2989005 @default.
- W2945165639 hasConcept C71924100 @default.
- W2945165639 hasConceptScore W2945165639C121332964 @default.
- W2945165639 hasConceptScore W2945165639C29456083 @default.
- W2945165639 hasConceptScore W2945165639C2989005 @default.
- W2945165639 hasConceptScore W2945165639C71924100 @default.
- W2945165639 hasIssue "4" @default.
- W2945165639 hasLocation W29451656391 @default.
- W2945165639 hasLocation W29451656392 @default.
- W2945165639 hasLocation W29451656393 @default.
- W2945165639 hasLocation W29451656394 @default.
- W2945165639 hasLocation W29451656395 @default.
- W2945165639 hasLocation W29451656396 @default.
- W2945165639 hasOpenAccess W2945165639 @default.
- W2945165639 hasPrimaryLocation W29451656391 @default.
- W2945165639 hasRelatedWork W1506200166 @default.
- W2945165639 hasRelatedWork W1995515455 @default.
- W2945165639 hasRelatedWork W2080531066 @default.
- W2945165639 hasRelatedWork W2748952813 @default.
- W2945165639 hasRelatedWork W2899084033 @default.
- W2945165639 hasRelatedWork W2935759653 @default.
- W2945165639 hasRelatedWork W3031052312 @default.
- W2945165639 hasRelatedWork W3032375762 @default.
- W2945165639 hasRelatedWork W3105167352 @default.
- W2945165639 hasRelatedWork W3108674512 @default.
- W2945165639 hasVolume "23" @default.
- W2945165639 isParatext "false" @default.